Enforced	0	8	O
expression	9	19	O
of	20	22	O
tissue	23	29	B-Gene_or_gene_product
inhibitor	30	39	I-Gene_or_gene_product
of	40	42	I-Gene_or_gene_product
matrix	43	49	I-Gene_or_gene_product
metalloproteinase	50	67	I-Gene_or_gene_product
-	67	68	I-Gene_or_gene_product
3	68	69	I-Gene_or_gene_product
affects	70	77	O
functional	78	88	O
capillary	89	98	B-Tissue
morphogenesis	99	112	O
and	113	116	O
inhibits	117	125	O
tumor	126	131	B-Pathological_formation
growth	132	138	O
in	139	141	O
a	142	143	O
murine	144	150	B-Organism
tumor	151	156	B-Pathological_formation
model	157	162	O
.	162	163	O

Homeostasis	165	176	O
of	177	179	O
the	180	183	O
extracellular	184	197	B-Cellular_component
matrix	198	204	I-Cellular_component
is	205	207	O
a	208	209	O
delicate	210	218	O
balance	219	226	O
between	227	234	O
degradation	235	246	O
and	247	250	O
remodeling	251	261	O
,	261	262	O
the	263	266	O
balance	267	274	O
being	275	280	O
maintained	281	291	O
by	292	294	O
the	295	298	O
interaction	299	310	O
of	311	313	O
activated	314	323	O
matrix	324	330	B-Gene_or_gene_product
metalloproteinases	331	349	I-Gene_or_gene_product
(	350	351	O
MMPs	351	355	B-Gene_or_gene_product
)	355	356	O
and	357	360	O
specific	361	369	O
tissue	370	376	B-Gene_or_gene_product
inhibitors	377	387	I-Gene_or_gene_product
of	388	390	I-Gene_or_gene_product
matrix	391	397	I-Gene_or_gene_product
metalloproteinases	398	416	I-Gene_or_gene_product
(	417	418	O
TIMPs	418	423	B-Gene_or_gene_product
)	423	424	O
.	424	425	O

Up	426	428	O
-	428	429	O
regulation	429	439	O
of	440	442	O
MMP	443	446	B-Gene_or_gene_product
activity	447	455	O
,	455	456	O
favoring	457	465	O
proteolytic	466	477	O
degradation	478	489	O
of	490	492	O
the	493	496	O
basement	497	505	B-Cellular_component
membrane	506	514	I-Cellular_component
and	515	518	O
extracellular	519	532	B-Cellular_component
matrix	533	539	I-Cellular_component
,	539	540	O
has	541	544	O
been	545	549	O
linked	550	556	O
to	557	559	O
tumor	560	565	B-Pathological_formation
growth	566	572	O
and	573	576	O
metastasis	577	587	O
,	587	588	O
as	589	591	O
well	592	596	O
as	597	599	O
tumor	600	605	B-Pathological_formation
-	605	606	O
associated	606	616	O
angiogenesis	617	629	O
,	629	630	O
whereas	631	638	O
inhibition	639	649	O
of	650	652	O
MMP	653	656	B-Gene_or_gene_product
activity	657	665	O
appears	666	673	O
to	674	676	O
restrict	677	685	O
these	686	691	O
processes	692	701	O
.	701	702	O

We	703	705	O
have	706	710	O
used	711	715	O
retroviral	716	726	O
-	726	727	O
mediated	727	735	O
gene	736	740	O
delivery	741	749	O
to	750	752	O
effect	753	759	O
sustained	760	769	O
autocrine	770	779	O
expression	780	790	O
of	791	793	O
TIMP	794	798	B-Gene_or_gene_product
-	798	799	I-Gene_or_gene_product
3	799	800	I-Gene_or_gene_product
in	801	803	O
murine	804	810	B-Organism
neuroblastoma	811	824	B-Cell
and	825	828	O
melanoma	829	837	B-Cell
tumor	838	843	I-Cell
cells	844	849	I-Cell
in	850	852	O
order	853	858	O
to	859	861	O
further	862	869	O
examine	870	877	O
the	878	881	O
ability	882	889	O
of	890	892	O
TIMPs	893	898	B-Gene_or_gene_product
to	899	901	O
inhibit	902	909	O
angiogenesis	910	922	O
in	923	925	O
vivo	926	930	O
.	930	931	O

Growth	932	938	O
of	939	941	O
both	942	946	O
histologic	947	957	O
types	958	963	O
of	964	966	O
gene	967	971	O
-	971	972	O
modified	972	980	O
tumor	981	986	B-Cell
cells	987	992	I-Cell
in	993	995	O
severe	996	1002	O
combined	1003	1011	O
immunodeficiency	1012	1028	O
(	1029	1030	O
SCID	1030	1034	O
)	1034	1035	O
mice	1036	1040	B-Organism
was	1041	1044	O
significantly	1045	1058	O
restricted	1059	1069	O
when	1070	1074	O
compared	1075	1083	O
with	1084	1088	O
controls	1089	1097	O
.	1097	1098	O

Grossly	1099	1106	O
,	1106	1107	O
these	1108	1113	O
tumors	1114	1120	B-Pathological_formation
were	1121	1125	O
small	1126	1131	O
and	1132	1135	O
had	1136	1139	O
few	1140	1143	O
feeding	1144	1151	B-Multi-tissue_structure
vessels	1152	1159	I-Multi-tissue_structure
.	1159	1160	O

Histologic	1161	1171	O
evaluation	1172	1182	O
revealed	1183	1191	O
that	1192	1196	O
although	1197	1205	O
tumors	1206	1212	B-Pathological_formation
overexpressing	1213	1227	O
TIMP	1228	1232	B-Gene_or_gene_product
-	1232	1233	I-Gene_or_gene_product
3	1233	1234	I-Gene_or_gene_product
had	1235	1238	O
an	1239	1241	O
increased	1242	1251	O
number	1252	1258	O
of	1259	1261	O
CD31	1262	1266	B-Gene_or_gene_product
(	1266	1267	O
+	1267	1268	O
)	1268	1269	O
endothelial	1270	1281	O
cells	1282	1287	O
,	1287	1288	O
these	1289	1294	O
endothelial	1295	1306	B-Cell
cells	1307	1312	I-Cell
had	1313	1316	O
not	1317	1320	O
formed	1321	1327	O
functional	1328	1338	O
tubules	1339	1346	B-Tissue
,	1346	1347	O
as	1348	1350	O
evidenced	1351	1360	O
by	1361	1363	O
decreased	1364	1373	O
vessel	1374	1380	B-Multi-tissue_structure
continuity	1381	1391	O
and	1392	1395	O
minimal	1396	1403	O
pericyte	1404	1412	B-Cell
recruitment	1413	1424	O
.	1424	1425	O

This	1426	1430	O
effect	1431	1437	O
appears	1438	1445	O
to	1446	1448	O
be	1449	1451	O
mediated	1452	1460	O
,	1460	1461	O
in	1462	1464	O
part	1465	1469	O
,	1469	1470	O
by	1471	1473	O
decreased	1474	1483	O
expression	1484	1494	O
of	1495	1497	O
vascular	1498	1506	B-Gene_or_gene_product
endothelial	1507	1518	I-Gene_or_gene_product
(	1519	1520	I-Gene_or_gene_product
VE	1520	1522	I-Gene_or_gene_product
)	1522	1523	I-Gene_or_gene_product
-	1523	1524	I-Gene_or_gene_product
cadherin	1524	1532	I-Gene_or_gene_product
by	1533	1535	O
endothelial	1536	1547	B-Cell
cells	1548	1553	I-Cell
in	1554	1556	O
the	1557	1560	O
presence	1561	1569	O
of	1570	1572	O
TIMP	1573	1577	B-Gene_or_gene_product
-	1577	1578	I-Gene_or_gene_product
3	1578	1579	I-Gene_or_gene_product
as	1580	1582	O
seen	1583	1587	O
both	1588	1592	O
in	1593	1595	O
an	1596	1598	O
in	1599	1601	O
vitro	1602	1607	O
assay	1608	1613	O
and	1614	1617	O
in	1618	1620	O
TIMP	1621	1625	B-Gene_or_gene_product
-	1625	1626	I-Gene_or_gene_product
3	1626	1627	I-Gene_or_gene_product
-	1627	1628	O
overexpressing	1628	1642	O
tumors	1643	1649	B-Pathological_formation
.	1649	1650	O

Taken	1651	1656	O
together	1657	1665	O
,	1665	1666	O
these	1667	1672	O
results	1673	1680	O
demonstrate	1681	1692	O
that	1693	1697	O
overexpression	1698	1712	O
of	1713	1715	O
TIMP	1716	1720	B-Gene_or_gene_product
-	1720	1721	I-Gene_or_gene_product
3	1721	1722	I-Gene_or_gene_product
can	1723	1726	O
inhibit	1727	1734	O
angiogenesis	1735	1747	O
and	1748	1751	O
associated	1752	1762	O
tumor	1763	1768	B-Pathological_formation
growth	1769	1775	O
,	1775	1776	O
and	1777	1780	O
that	1781	1785	O
the	1786	1789	O
antiangiogenic	1790	1804	O
effects	1805	1812	O
of	1813	1815	O
TIMP	1816	1820	B-Gene_or_gene_product
-	1820	1821	I-Gene_or_gene_product
3	1821	1822	I-Gene_or_gene_product
appear	1823	1829	O
to	1830	1832	O
be	1833	1835	O
mediated	1836	1844	O
through	1845	1852	O
the	1853	1856	O
inhibition	1857	1867	O
of	1868	1870	O
functional	1871	1881	O
capillary	1882	1891	B-Tissue
morphogenesis	1892	1905	O
.	1905	1906	O

